Morr F
Developed to mitigate androgenic hair loss to support hair follicle density and target local scalp microcirculation.
- Category
- Hair Loss
- Active ingredients
- Minoxidil · Finasteride
- Route
- Cutaneous use
- Form
- Oral Solution
- Strengths
- 5% 60ml
Prescription and consultation requirements for Morr F vary by destination and are determined by the fulfilment partner.
Morr F details
- Condition
- Androgenetic Alopecia
- Alternative names
- minoxidil, finasteride
- Therapeutic class
- Vasodilator, 5-Alpha Reductase Inhibitor Combination
- Pharmacological class
- Topical Hair Regrowth Therapy
- Contraindications
- pregnancy; hypersensitivity to any component; broken scalp skin
- Minor side effects
- local itching; scalp dryness; mild scaling
- Moderate side effects
- erythema; burning sensation; mild hypertrichosis
- Serious side effects
- severe localised hypersensitivity, requires immediate medical attention
- Dosage forms
- Oral Solution
- Administration route
- Cutaneous use
- Supply category
- Prescription-only medicine (POM)
- Manufacturer
- Intas Pharmaceuticals Ltd
- Onset Time
- 2–4 months
- Storage instructions
- Store below 25°C.
- Age restrictions
- Approved for adult males.
Patient summary
developed to mitigate androgenic hair loss to support hair follicle density and target local scalp microcirculation.
Mechanism of action
Minoxidil promotes scalp blood circulation while finasteride inhibits local DHT conversion to preserve hair follicles.
Pregnancy and breastfeeding
TGA Category X: Highly contraindicated. Finasteride is teratogenic. Breastfeeding: Not applicable.